The startup will also use its generative AI technology to optimize manufacturing of the gene therapy, leveraging data that MeiraGTx has amassed over the course of nearly a decade developing its ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

Any use of AI – or even less sophisticated methods of standardization ... Demand for apheresis for this population has grown recently in no small part due to the recent approval of two gene therapies, ...

Traditional methods for identifying therapeutic gene targets, crucial for personalized medicine, are expensive and time-consuming. While artificial intelligence (AI), particularly deep learning ...

Gene Munster, Deepwater Asset Management managing partner, joins 'Closing Bell' to discuss the AI tech trade and his outlook ...

Artificial intelligence company Hologen AI has committed up to $430 million as part of a multifaceted agreement to help take MeiraGTx’s Parkinson’s disease gene therapy all the way to market.

AI researchers are celebrating a medical breakthrough: a new AI algorithm developed by a team of US researchers can detect ...

We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at ...

“The first wave of CRISPR therapies has focused on a small number of monogenic diseases caused by single-gene mutations. By bringing together AWS’s powerful cloud computing and AI solutions ...

Elon Musk's legal dispute against OpenAI could affect the future of one of the most prominent leaders in artificial ...